Cfra began coverage on shares of Insulet (NASDAQ:PODD) in a report issued on Tuesday morning, Briefing.com Automated Import reports. The firm issued a sell rating and a $163.00 price objective on the medical instruments supplier’s stock.
Other analysts have also recently issued research reports about the stock. Guggenheim cut shares of Insulet from a buy rating to a neutral rating in a report on Thursday, October 3rd. They noted that the move was a valuation call. Leerink Swann reissued an outperform rating and set a $185.00 target price (up from $160.00) on shares of Insulet in a research note on Tuesday, September 24th. BTIG Research cut shares of Insulet from a buy rating to a neutral rating in a research report on Monday, October 14th. Canaccord Genuity raised their price target on shares of Insulet from $150.00 to $165.00 and gave the company a hold rating in a research note on Monday. Finally, Cowen set a $165.00 price target on Insulet and gave the company a buy rating in a report on Monday, October 21st. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and nine have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Hold and an average target price of $153.47.
Shares of NASDAQ PODD traded up $1.38 during mid-day trading on Tuesday, hitting $174.66. The company had a trading volume of 1,678 shares, compared to its average volume of 855,163. Insulet has a 12 month low of $70.80 and a 12 month high of $187.25. The stock has a market cap of $11.14 billion, a price-to-earnings ratio of 3,480.00 and a beta of 1.04. The company has a debt-to-equity ratio of 6.55, a current ratio of 7.01 and a quick ratio of 6.21. The firm’s 50 day simple moving average is $169.97 and its two-hundred day simple moving average is $144.63.
Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Tuesday, November 5th. The medical instruments supplier reported $0.01 EPS for the quarter, missing the Zacks’ consensus estimate of $0.03 by ($0.02). The company had revenue of $192.12 million for the quarter, compared to the consensus estimate of $179.50 million. Insulet had a return on equity of 10.34% and a net margin of 2.38%. Insulet’s quarterly revenue was up 27.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.03 earnings per share. Equities analysts forecast that Insulet will post 0.26 earnings per share for the current year.
In other news, CEO Shacey Petrovic sold 689 shares of the company’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $145.69, for a total value of $100,380.41. Following the completion of the sale, the chief executive officer now owns 94,510 shares in the company, valued at $13,769,161.90. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director John A. Fallon sold 14,525 shares of the firm’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $181.21, for a total value of $2,632,075.25. Company insiders own 3.50% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in PODD. Janus Henderson Group PLC grew its position in Insulet by 4.9% in the second quarter. Janus Henderson Group PLC now owns 369,611 shares of the medical instruments supplier’s stock worth $44,124,000 after buying an additional 17,328 shares during the last quarter. Handelsbanken Fonder AB acquired a new stake in shares of Insulet in the third quarter worth $3,299,000. Swiss National Bank boosted its position in shares of Insulet by 2.4% in the second quarter. Swiss National Bank now owns 110,300 shares of the medical instruments supplier’s stock worth $13,168,000 after buying an additional 2,600 shares during the period. Jennison Associates LLC grew its holdings in shares of Insulet by 53.6% during the second quarter. Jennison Associates LLC now owns 283,817 shares of the medical instruments supplier’s stock valued at $33,882,000 after buying an additional 98,995 shares in the last quarter. Finally, Columbus Circle Investors raised its position in Insulet by 74.6% during the second quarter. Columbus Circle Investors now owns 165,863 shares of the medical instruments supplier’s stock valued at $19,801,000 after buying an additional 70,860 shares during the period.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod.
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.